Shockwave Medical announced today that it unveiled a new coronary intravascular lithotripsy (IVL) catheter in the U.S. The planned introduction of the Shockwave C2+ coronary IVL catheter follows the receipt of FDA approval. This catheter offers 50% more pulses per catheter than the Shockwave C2 catheter that the FDA approved in June … [Read more...] about Shockwave Medical launches new coronary IVL catheter following FDA approval
Shockwave Medical
The top catheter innovation news stories of 2023 — so far
The world of catheter innovation has already seen remarkable strides this year— with some of the most promising medtech delivered into the body via catheter-based procedures. Think of improved ablation for treating AFib, coronary intravascular lithotripsy to combat coronary artery disease, and more. Here, we've highlighted the top five … [Read more...] about The top catheter innovation news stories of 2023 — so far
Shockwave Medical launches new coronary IVL catheter
Shockwave Medical (Nasdaq:SWAV) today announced full commercial availability for its C2+ coronary intravascular lithotripsy (IVL) catheter. The company designed its C2+ coronary IVL catheter to treat severely calcified coronary artery disease. Santa Clara, California-based Shockwave, which has been subject to recent acquisition speculation, … [Read more...] about Shockwave Medical launches new coronary IVL catheter
Shockwave Medical completes Neovasc acquisition
Shockwave Medical (Nasdaq:SWAV) announced today that it completed its $147 million acquisition of Neovasc. In January, Shockwave announced an agreement to acquire all of the issued and outstanding common shares of Neovasc. The company paid $27.25 per share upfront by way of a statutory plan of arrangement. The deal has an enterprise value of … [Read more...] about Shockwave Medical completes Neovasc acquisition
Shockwave Medical to acquire Neovasc for up to $147M
Shockwave Medical (NSDQ:SWAV) this week announced it signed an agreement to acquire all of the issued and outstanding common shares of Neovasc (NSDQ:NVCN). Neovasc enrolled its first patient in a clinical trial studying the Neovasc Reducer in January 2022. The company designed the device to reduce angina symptoms in people with refractory … [Read more...] about Shockwave Medical to acquire Neovasc for up to $147M
